Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives Average Rating of “Hold” from Analysts

Shares of Akoya Biosciences, Inc. (NASDAQ:AKYA) have received an average rating of “Hold” from the seven ratings firms that are covering the company, Marketbeat reports. Five research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $5.43.

Several equities analysts have recently issued reports on the stock. Piper Sandler reissued an “overweight” rating and issued a $3.00 price target (down previously from $4.00) on shares of Akoya Biosciences in a report on Tuesday, November 19th. Craig Hallum lowered shares of Akoya Biosciences from a “buy” rating to a “hold” rating and reduced their target price for the stock from $7.00 to $5.00 in a research note on Friday, November 15th. Finally, Canaccord Genuity Group lowered shares of Akoya Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th.

Hedge Funds Weigh In On Akoya Biosciences

Large investors have recently modified their holdings of the business. SG Americas Securities LLC acquired a new position in shares of Akoya Biosciences during the 4th quarter worth about $28,000. Barclays PLC boosted its stake in shares of Akoya Biosciences by 320.9% during the 3rd quarter. Barclays PLC now owns 39,472 shares of the company’s stock worth $107,000 after buying an additional 30,095 shares during the last quarter. State Street Corp boosted its stake in shares of Akoya Biosciences by 4.2% during the 3rd quarter. State Street Corp now owns 453,296 shares of the company’s stock worth $1,233,000 after buying an additional 18,361 shares during the last quarter. GSA Capital Partners LLP boosted its stake in shares of Akoya Biosciences by 87.4% during the 3rd quarter. GSA Capital Partners LLP now owns 310,669 shares of the company’s stock worth $845,000 after buying an additional 144,903 shares during the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of Akoya Biosciences by 39.6% during the 4th quarter. Bank of America Corp DE now owns 29,092 shares of the company’s stock worth $67,000 after buying an additional 8,258 shares during the last quarter. 79.42% of the stock is currently owned by institutional investors and hedge funds.

Akoya Biosciences Price Performance

Shares of AKYA stock opened at $2.06 on Tuesday. Akoya Biosciences has a 12-month low of $1.88 and a 12-month high of $6.31. The firm has a market capitalization of $101.87 million, a price-to-earnings ratio of -1.74 and a beta of 1.23. The company has a quick ratio of 1.85, a current ratio of 2.75 and a debt-to-equity ratio of 5.62. The firm has a fifty day moving average of $2.58 and a 200-day moving average of $2.61.

About Akoya Biosciences

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.